thanks. published 2021 so Deloitte did not yet took note of the trial results for sensitivity and specificity in study 7. it also mentions:
"In any decision to transition to a new test type, it is important that the test is approved by the Therapeutic Goods Administration (as per the guidance in the NBCSP Quality Framework) and a cost-effectiveness analysis is performed using reliable estimates of test sensitivity and specificity, as compared with the current iFOBT."
so just waiting news from TGA.
Sept '21 Deloitte's review of the National Bowel Cancer Screening Program, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
